Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887744 | 0.85 | NOTUM (0.51) | SMN1; SMN2NPSR1TDP1MAPTHTT | |
| SCHEMBL8469388 | 0.81 | SCN5A (0.46) | SMN1; SMN2NPSR1TDP1MAPTHTT | |
| SCHEMBL4888769 | 0.80 | S1PR1 (0.38) | SMN1; SMN2MAPTHTTTSHRMAPK1 | |
| SCHEMBL4888645 | 0.77 | GRM5 (0.46) | SMN1; SMN2NPSR1TDP1MAPTMAPK1 | |
| SCHEMBL4885911 | 0.75 | NPC1 (0.57) | SMN1; SMN2NPSR1MAPTHTTTSHR | |
| SCHEMBL5178277 | 0.74 | NPSR1 (0.43) | SMN1; SMN2NPSR1TDP1MAPTHTT | |
| SCHEMBL4888552 | 0.74 | CA2 (0.39) | CA2CA9CA12CA1TP53 | |
| SCHEMBL4884698 | 0.72 | MAPT (0.49) | SMN1; SMN2MAPTTSHRKMT2ACA2 | |
| SCHEMBL4891054 | 0.72 | CA9 (0.49) | MAPTCA2CA9CA12CA1 | |
| SCHEMBL4891052 | 0.71 | CA9 (0.51) | CA2CA9CA12CA1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | SMN1; SMN2 4481/4885NPSR1 157/4885TDP1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.